D2.367 - Omalizumab Efficacy in Relapse of Nasal Polyposis

Chronic rhinosinusitis with nasal polyposis (CRSwNP) patients face  high relapse risk, impacting their quality of life. This clinical trial study assesses omalizumab's efficacy in reducing nasal polyp recurrence, improve management and outcomes through potential therapeutic interventions

patients with CRSwNP. Participants were randomized into control and omalizumab groups. Before  the intervention, demographic data, SNOT-22, TNSS, NPS, and blood IgE levels were collected. An oral aspirin challenge diagnosed AERD. Both groups were monitored, completing questionnaires during and 12 months post-study initiation. Recurrence of nasal polyps was examined at the one-year mark

76 participants (50 control, 26 omalizumab), aged around 45.62 and 41.50 years, the omalizumab group exhibited significantly higher IgE levels (342.65) compared to the control group (171.66, P<0.001). Both groups experienced a notable decrease in NPS, with the omalizumab group showing a greater reduction (-1.31 vs -0.90, P<0.001). TNSS scores dropped more in the omalizumab group (-4.54) than the control group (-2.04) at week 24. SNOT-22 scores decreased significantly from baseline to week 24 for both groups. Notably, nasal polyp relapse occurred in 9 control patients but none in the omalizumab group (P<0.001). No significant differences were observed between AERD and non-AERD patients.

Omalizumab is an effective treatment for CRSwNP, significantly improving the TNSS and clinical outcomes while reducing relapse frequency.